Haili Bio's M&A fund reduces capital, extends term

Shanghai Hile Bio-Technology (SSE:603718) announced changes to its Shanghai Runling M&A Fund. The fund will reduce its committed capital from ¥122.7 million to ¥100 million, returning ¥22.7 million to investors. Haili Bio will receive ¥3.17 million of this return. The fund's term will also be extended by two years to January 8, 2027, due to anticipated delays in portfolio company exits. Additionally, Haili Bio's controlling shareholder, Shanghai Haoyuan, will acquire ¥34.88 million worth of fund shares from other limited partners. This transaction constitutes a related transaction under Chinese regulations, but does not require shareholder approval. The changes aim to optimize capital deployment and ensure the fund's continued operation.